Predictors of Residual T1 High Grade on Re-Transurethral Resection in a Large Multi-Institutional Cohort of Patients with Primary T1 High-Grade/Grade 3 Bladder Cancer

被引:29
|
作者
Ferro, Matteo [1 ]
Di Lorenzo, Giuseppe [2 ]
Buonerba, Carlo [2 ,3 ]
Lucarelli, Giuseppe [4 ]
Russo, Giorgio Ivan [5 ]
Cantiello, Francesco [6 ]
Abu Farhan, Abdal Rahman [6 ]
Di Stasi, Savino [7 ]
Musi, Gennaro [1 ]
Hurle, Rodolfo [8 ]
Vincenzo, Serretta [9 ]
Busetto, Gian Maria [10 ]
De Berardinis, Ettore [10 ]
Perdona, Sisto [11 ]
Borghesi, Marco [12 ]
Schiavina, Riccardo [12 ]
Almeida, Gilberto L. [13 ]
Bove, Pierluigi [14 ]
Lima, Estevao [15 ,16 ]
Grimaldi, Giovanni [15 ,16 ]
Matei, Deliu Victor [1 ]
Mistretta, Francesco Alessandro [1 ]
Crisan, Nicolae [17 ]
Terracciano, Daniela [18 ]
Paolo, Verze [19 ]
Battaglia, Michele [2 ]
Guazzoni, Giorgio [8 ]
Autorino, Riccardo [20 ]
Morgia, Giuseppe [3 ]
Damiano, Rocco [4 ]
Muto, Matteo [21 ]
La Rocca, Roberto [19 ]
Mirone, Vincenzo [19 ]
de Cobelli, Ottavio [1 ,22 ]
Vartolomei, Mihai Dorin [1 ,23 ]
机构
[1] European Inst Oncol, Div Urol, Milan, Italy
[2] Federico II Univ Naples, Dept Clin Med & Surg, Naples, Italy
[3] Ist Zooprofilatt Sperimentale Mezzogiorno, Portici, Italy
[4] Univ Bari, Dept Emergency & Organ Transplantat, Urol Androl & Kidney Transplantat Unit, Bari, Italy
[5] Univ Catania, Dept Urol, Catania, Italy
[6] Magna Graecia Univ Catanzaro, Dept Urol, Catanzaro, Italy
[7] Univ Rome, Urol Unit, Policlin Tor Vergata, Rome, Italy
[8] Clin & Res Hosp, Dept Urol, Ist Clin Humanitas, Milan, Italy
[9] Univ Palermo, Div Urol, Palermo, Italy
[10] Univ Roma La Sapienza, Dept Urol, Rome, Italy
[11] IRCCS, Ist Nazl Tumori Fdn G Pascale, Dept Urogynaecol Oncol, Naples, Italy
[12] Univ Bologna, Dept Urol, Bologna, Italy
[13] Univ Vale Itajai, Dept Urol, Itajal, Brazil
[14] Azienda Policlin Tor Vergata, Urol Unit, Dept Expt Med & Surg, Rome, Italy
[15] Univ Minho, Sch Med, Dept CUF Urol, Minho, Portugal
[16] Univ Minho, Sch Med, Life & Hlth Sci Res Inst, Minho, Portugal
[17] Univ Med & Pharm Iuliu Hatieganu, Dept Urol, Cluj Napoca, Romania
[18] Univ Naples Federico II, Dept Translat Med Sci, Naples, Italy
[19] Univ Naples Federico II, Dept Neurosci Sci Reprod & Odontostomatol, Urol Unit, Naples, Italy
[20] Virginia Commonwealth Univ, Div Urol, Richmond, VA USA
[21] Univ Naples Federico II, Dept Clin Med & Surg, Med Sch Naples, Naples, Italy
[22] Univ Milan, Milan, Italy
[23] Univ Med & Pharm, Dept Cell & Mol Biol, Targu Mures, Romania
来源
JOURNAL OF CANCER | 2018年 / 9卷 / 22期
关键词
bladder cancer; neutrophil-to-lymphocytes ratio; re-transurethral resection; high-grade; LYMPHOCYTE RATIO; RISK-FACTORS; TUMOR; OBESITY; TUR; METAANALYSIS; NEUTROPHIL; RECURRENCE; OUTCOMES;
D O I
10.7150/jca.26129
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The aim of this multi-institutional study was to identify predictors of residual high-grade (HG) disease at re-transurethral resection (reTUR) in a large cohort of primary T1 HG/Grade 3 (G3) bladder cancer patients. A total of 1155 patients with primary T1 HG/G3 bladder cancer from 13 academic institutions that underwent a reTUR within 6 weeks after first TUR were evaluated. Logistic regression analysis was performed to assess the association of predictive factors with residual HG at reTUR. Residual HG cancer was found in 288 (24.9%) of patients at reTUR. Patients presenting residual HG cancer were more likely to have carcinoma in situ (CIS) at first resection (p<0.001), multiple tumors (p=0.02), and tumor size larger than 3 cm (p=0.02). Residual HG disease at reTUR was associated with increased preoperative neutrophil-to-lymphocytes ratio (NLR) (p=0.006) and body mass index BMI)>=25 kg/m(2). On multivariable analysis, independent predictors for HG residual disease at reTUR were tumor size >3cm (OR = 1.37; 95% CI: 1.02-1.84, p=0.03), concomitant CIS (OR 1.92; 95% CI: 1.32-2.78, p=0.00I), being overweight (OR= 2.08; 95% CI: 1.44-3.01, p<0.001) and obesity (OR 2.48; 95% CI: 1.64-3.77, p<0.001). A reTUR in high grade T1 bladder cancer is mandatory as about 25% of patients, presents residual high grade disease. Independent predictors to identify patients at risk of residual high grade disease after a complete TUR include tumor size, presence of carcinoma in situ, and BMI >=25 kg/m(2).
引用
收藏
页码:4250 / 4254
页数:5
相关论文
共 50 条
  • [1] High-Grade T1 on Re-Transurethral Resection after Initial High-Grade T1 Confers Worse Oncological Outcomes: Results of a Multi-Institutional Study
    Ferro, Matteo
    Vartolomei, Mihai Dorin
    Cantiello, Francesco
    Lucarelli, Giuseppe
    Di Stasi, Savino M.
    Hurle, Rodolfo
    Guazzoni, Giorgio
    Busetto, Gian Maria
    De Berardinis, Ettore
    Damiano, Rocco
    Perdona, Sisto
    Borghesi, Marco
    Schiavina, Riccardo
    Almeida, Gilberto L.
    Bove, Pierluigi
    Lima, Estevao
    Grimaldi, Giovanni
    Autorino, Riccardo
    Crisan, Nicolae
    Abu Farhan, Abdal Rahman
    Verze, Paolo
    Battaglia, Michele
    Serretta, Vincenzo
    Russo, Giorgio Ivan
    Morgia, Giuseppe
    Musi, Gennaro
    de Cobelli, Ottavio
    Mirone, Vincenzo
    Shariat, Shahrokh F.
    [J]. UROLOGIA INTERNATIONALIS, 2018, 101 (01) : 7 - 15
  • [2] Re: The Impact of Re-Transurethral Resection on Clinical Outcomes in a Large Multicentre Cohort of Patients with T1 High-Grade/Grade 3 Bladder Cancer Treated with bacille Calmette-Guerin
    Chang, Sam S.
    [J]. JOURNAL OF UROLOGY, 2018, 199 (02): : 340 - 340
  • [3] The impact of re-transurethral resection on clinical outcomes in a large multicentre cohort of patients with T1 high-grade/Grade 3 bladder cancer treated with bacille Calmette-Guerin
    Gontero, Paolo
    Sylvester, Richard
    Pisano, Francesca
    Joniau, Steven
    Oderda, Marco
    Serretta, Vincenzo
    Larre, Stephane
    Di Stasi, Savino
    Van Rhijn, Bas
    Witjes, Alfred J.
    Grotenhuis, Anne J.
    Colombo, Renzo
    Briganti, Alberto
    Babjuk, Marek
    Soukup, Viktor
    Malmstrom, Per-Uno
    Irani, Jacques
    Malats, Nuria
    Baniel, Jack
    Mano, Roy
    Cai, Tommaso
    Cha, Eugene K.
    Ardelt, Peter
    Vakarakis, John
    Bartoletti, Riccardo
    Dalbagni, Guido
    Shariat, Shahrokh F.
    Xylinas, Evanguelos
    Karnes, Robert J.
    Palou, Joan
    [J]. BJU INTERNATIONAL, 2016, 118 (01) : 44 - 52
  • [4] Results of second transurethral resection for high-grade T1 bladder cancer
    Hashine, Katsuyoshi
    Ide, Takehiro
    Nakashima, Takeshi
    Hosokawa, Tadanori
    Ninomiya, Iku
    Teramoto, Norihiro
    [J]. UROLOGY ANNALS, 2016, 8 (01) : 10 - 15
  • [5] Is Repeat Transurethral Resection Always Needed in High-Grade T1 Bladder Cancer?
    Calo, Beppe
    Chirico, Marco
    Fortunato, Francesca
    Sanguedolce, Francesca
    Carvalho-Dias, Emanuel
    Autorino, Riccardo
    Carrieri, Giuseppe
    Cormio, Luigi
    [J]. FRONTIERS IN ONCOLOGY, 2019, 9
  • [6] HIGH-GRADE T1 BLADDER CANCER: IS A SECOND RESECTION IMPERATIVE?
    Branchereau, Julien
    Luyckx, Francois
    Karam, Georges
    Bouchot, Olivier
    Rigaud, Jerome
    [J]. JOURNAL OF UROLOGY, 2011, 185 (04): : E700 - E700
  • [7] Radiotherapy for High-grade T1 Bladder Cancer
    Raby, Sophie E. M.
    Choudhury, Ananya
    [J]. EUROPEAN UROLOGY FOCUS, 2018, 4 (04): : 506 - 508
  • [8] Should fluorescence cystoscopy be used for transurethral resection in patients with high-grade T1 bladder cancer?
    Katz, Mark H.
    Steinberg, Gary D.
    [J]. NATURE CLINICAL PRACTICE UROLOGY, 2008, 5 (09): : 472 - 473
  • [9] Should fluorescence cystoscopy be used for transurethral resection in patients with high-grade T1 bladder cancer?
    Mark H Katz
    Gary D Steinberg
    [J]. Nature Clinical Practice Urology, 2008, 5 : 472 - 473
  • [10] Is a second transurethral resection of high-grade T1 bladder tumors always necessary?
    Mark, James Ryan
    Drury, Nicholas Brent
    Merwarth, Caroline Arden
    Gaston, Kris E.
    Roy, Ornob Proteek
    Riggs, Stephen Boyd
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)